Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Biofluid Biopsies
Conferences  \  Biofluid Biopsies & High-Value Diagnostics 2015  \  Biofluid Biopsies  \  Agenda  \  Oscar Puig
RegisterLogin

Oscar Puig's Biography


Oscar Puig, Biomarker Leader, Hoffmann La Roche

Oscar Puig is a Biomarker and Experimental Medicine Leader in Oncology at the Translational Clinical Research Center, Roche, where he joined in 2012. Prior to that, he was an Associate Director in the department of Informatics and Analysis, Merck Research Labs. He earned his Ph.D. at the University of Valencia, Spain, and carried out postdoctoral research at the European Molecular Biology Laboratory, in Heidelberg, Germany, and in the lab of Bob Tjian, at UC Berkeley, CA. Before joining Merck in 2006, he held an independent position as a group leader at the University of Helsinki, where he is a docent. Dr Puig has over 40 publications in peer-reviewed journals. His interest is the development and implementation of biomarkers in Clinical Oncology.

Oscar Puig Image

Liquid Biopsies in NSCLC

Tuesday, 17 November 2015 at 15:00

Add to Calendar ▼2015-11-17 15:00:002015-11-17 16:00:00Europe/LondonLiquid Biopsies in NSCLCSELECTBIOenquiries@selectbiosciences.com

ALK inhibitors have shown efficacy in Non-Small Cell Lung cancer (NSCLC) patients whose tumors have activating rearrangements comprising ALK kinase. ALK rearrangements are routinely assessed in formalin-fixed samples by FISH, IHC or NGS. Unfortunately, patients progress after therapy with ALK inhibitors because of the appearance of secondary activating mutations in ALK and other escape pathways, which leads to acquired resistance. Quantitative assessment of dynamic changes of ALK rearrangement in plasma could be used as an indicator of initial treatment response, and appearance of secondary mutations could indicate development of acquired resistance.  We will present data from plasma samples of patients enrolled in phase 2 studies treated with the ALK inhibitor alectinib. These results suggest that cell free DNA in plasma is a useful method to assess response and resistance in NSCLC.

Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors